Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBV-MPL vaccine formulation B
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**HBV-MPL vaccine formulation B** was an investigational GSK recombinant hepatitis B prophylactic vaccine formulation containing hepatitis B surface antigen and the immunostimulatory adjuvant monophosphoryl lipid A. It was designed to induce protective active immunity against hepatitis B virus infection and was evaluated as a two-dose intramuscular regimen administered at months 0 and 6, including in healthy adolescents in a Phase 2 study comparing two HBV-MPL formulations with Engerix-B. ([gsk-studyregister.com](https://www.gsk-studyregister.com/trials/208129%2F028))
- Brand names
- Fendrix
- Other names
- HBV-MPL vaccine Formulation B
02
Targets
TLR4 (Toll-like receptor 4)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HBV-MPL vaccine formulation B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBV-MPL vaccine formulation B.